东方生物
(688298)
| 流通市值：39.07亿 | | | 总市值：39.07亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 464,165,739.75 | 256,264,814.4 | 947,379,903.5 | 671,812,093.43 |
| 营业收入 | 464,165,739.75 | 256,264,814.4 | 947,379,903.5 | 671,812,093.43 |
| 二、营业总成本 | 666,531,461.19 | 346,307,060.81 | 1,341,786,186.68 | 898,681,964.69 |
| 营业成本 | 261,701,203.62 | 146,343,305.53 | 560,899,414.12 | 392,089,040.09 |
| 税金及附加 | 9,847,496.27 | 4,781,421.33 | 19,874,555.65 | 10,573,098.29 |
| 销售费用 | 81,671,910.31 | 42,942,552.49 | 190,988,640.32 | 133,863,869.99 |
| 管理费用 | 199,149,567.36 | 92,700,153.02 | 402,307,015.1 | 271,240,920.05 |
| 研发费用 | 80,145,608.88 | 42,007,384.36 | 230,811,644.92 | 163,552,038.82 |
| 财务费用 | 34,015,674.75 | 17,532,244.08 | -63,095,083.43 | -72,637,002.55 |
| 其中:利息费用 | 4,981,784.68 | 2,515,595.17 | 9,908,990.32 | 7,490,870.56 |
| 其中:利息收入 | 50,000,713.68 | 32,802,993.74 | 80,351,790.22 | 70,570,633.38 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,245,811.82 | 3,038,506.56 | -1,596,613.77 | 4,987,783.59 |
| 加:投资收益 | 11,913,758.29 | 7,098,406.57 | 8,681,541.5 | 5,520,335.43 |
| 净敞口套期收益 | - | - | 0 | - |
| 汇兑收益 | - | - | 0 | - |
| 资产处置收益 | 1,121,234.68 | 573,989.4 | 1,748,605.93 | 1,678,614.11 |
| 资产减值损失(新) | -13,558,090.52 | -11,642,070.82 | -199,366,343.14 | -16,473,020.48 |
| 信用减值损失(新) | -4,150,220.22 | -4,004,163.41 | -7,919,960.07 | -6,271,653.33 |
| 其他收益 | 3,461,719.93 | 2,161,269.36 | 10,614,265.82 | 3,211,237.36 |
| 四、营业利润 | -202,331,507.46 | -92,816,308.75 | -582,244,786.91 | -234,216,574.58 |
| 加:营业外收入 | 164,094.71 | 2,826.09 | 776,755.75 | 299,801.03 |
| 减:营业外支出 | 1,162,433.97 | 12,404.11 | 2,025,806.33 | 806,307.95 |
| 五、利润总额 | -203,329,846.72 | -92,825,886.77 | -583,493,837.49 | -234,723,081.5 |
| 减:所得税费用 | 28,731,150.34 | 5,875,309.3 | 13,911,370.06 | -3,548,893.96 |
| 六、净利润 | -232,060,997.06 | -98,701,196.07 | -597,405,207.55 | -231,174,187.54 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -232,060,997.06 | -98,701,196.07 | -597,405,207.55 | -231,174,187.54 |
| 终止经营净利润 | - | - | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -222,229,817.44 | -93,843,129.17 | -573,598,190.08 | -212,632,127.27 |
| 少数股东损益 | -9,831,179.62 | -4,858,066.9 | -23,807,017.47 | -18,542,060.27 |
| 扣除非经常损益后的净利润 | -237,982,747.33 | -105,413,891.47 | -597,472,097.82 | -231,972,814.13 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.16 | -0.49 | -2.98 | -1.1 |
| (二)稀释每股收益 | -1.16 | -0.49 | -2.98 | -1.1 |
| 八、其他综合收益 | -16,066,354.42 | -4,955,418.9 | -28,782,723.77 | -21,790,105.27 |
| 归属于母公司股东的其他综合收益 | -16,066,354.42 | -4,955,418.9 | -28,782,723.77 | -21,790,105.27 |
| 九、综合收益总额 | -248,127,351.48 | -103,656,614.97 | -626,187,931.32 | -252,964,292.81 |
| 归属于母公司股东的综合收益总额 | -238,296,171.86 | -98,798,548.07 | -602,380,913.85 | -234,422,232.54 |
| 归属于少数股东的综合收益总额 | -9,831,179.62 | -4,858,066.9 | -23,807,017.47 | -18,542,060.27 |
| 公告日期 | 2026-08-29 | 2026-04-29 | 2026-04-29 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |